Telix Pharmaceuticals (NASDAQ:TLX) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a report issued on Monday,Benzinga reports. The firm currently has a $22.00 price target on the stock.

A number of other brokerages have also recently commented on TLX. Citigroup upped their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Stock Up 6.6%

Shares of TLX stock opened at $11.24 on Monday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The firm’s 50 day moving average is $7.98 and its 200 day moving average is $8.71. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $20.00.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. As a group, research analysts expect that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals during the 4th quarter valued at $89,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $213,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals during the 4th quarter valued at $111,000. Finally, Private Advisor Group LLC grew its holdings in shares of Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares during the last quarter.

More Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix and Regeneron announced a strategic radiopharmaceutical collaboration to jointly develop and commercialize next‑generation radiopharma therapies, targeting solid tumors; the deal carries potential development and commercial scale benefits and was reported with deal economics described as up to $2.1 billion in potential value. This is a major validation for Telix’s technology and expands commercialization reach. Telix and Regeneron Announce Strategic Radiopharma Collaboration
• Positive Sentiment: Market coverage and headlines highlighted the Regeneron tie-up and its focus on solid‑tumor programs, prompting buying interest and headlines that Telix shares “jumped” on the deal — reinforcing the near‑term positive market reaction. Telix Pharmaceuticals Shares Jump on Regeneron Deal
• Positive Sentiment: Analysts reiterated bullish ratings and high price targets after the news: Wedbush reaffirmed an “outperform” with a $22 target and HC Wainwright kept a “buy” with a $20 target — both imply substantial upside from current levels and support continued investor interest. Benzinga
• Neutral Sentiment: Citi group entities dropped below the substantial holder threshold in Telix, per filings — a change in reported institutional ownership that is noteworthy for monitoring but not necessarily an immediate directional signal for the stock. Citi Group Entities Drop Below Substantial Holder Threshold in Telix Pharmaceuticals

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.